Archives — August 2016 back to current month (4)
The late-stage biopharmaceutical company Soligenix has had a string of good news. Revenue is up, the FDA awarded orphan status to a key drug, and BARDA and NIAID have granted the firm additional funding, plus the company is developing vaccines against Ebola and ricin, and has several other ongoing trials. Analyst Grant Zeng of Zacks Investment Research assesses the landscape.
Inovio Expands Ebola Vaccine Trial (08/24/2016)
Inovio Pharmaceuticals Inc. (INO:NASDAQ) has expanded the Phase 1 trial of its Ebola vaccine to include an additional 125 healthy subjects. This, according to Maxim Group analyst Jason Kolbert, will help the company determine an "optimal" strategy for intradermal (skin) vaccination.
The ASX: Investing in an Emerging Biotech Frontier (08/10/2016)
Concerned about investing in the life sciences in the United States, where markets have slumped in 2016 and the presidential election furthers volatility? NDF Research Founder Stuart Roberts makes an argument for taking a look at investment opportunities Down Under.
With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix has expanded its scope by initiating a Phase 1 study of the small molecule to further investigate its potential applications.
|"RP announced that it has identified two new two European manufacturers with which it will collaborate going forward on development of its patented Pelletier element cooled dermal injector RCI-02."|
|"I wanted to send out a quick update on DXD after two tremendous announcements last week that I believe the market totally missed, which is where we see a major buying opportunity."|
|"INO's revenues and R&D were slightly above our projections."|